Bristol-Myers Squibb (BMY) Announces Early Stoppage of Opdivo Phase 3 in SCCHN
Tweet Send to a Friend
Bristol-Myers Squibb Company (NYSE: BMY) announced that a randomized Phase 3 study evaluating Opdivo (nivolumab) versus investigator’s choice in patients ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
